Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Revenue (ASC 606) of $84.04 million for fiscal year 2025.
ELITE PHARMACEUTICALS INC /NV/ Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $84.04M | +48.4% |
| 2024 | $56.63M | +65.8% |
| 2023 | $34.16M | +5.9% |
| 2022 | $32.26M | +27.1% |
| 2021 | $25.38M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $31.59M | +119.9% | -13.0% |
| September 30, 2025 | $36.32M | +92.4% | -9.7% |
| June 30, 2025 | $40.21M | +113.9% | +179.9% |
| December 31, 2024 | $14.36M | -7.6% | -23.9% |
| September 30, 2024 | $18.88M | +33.4% | +0.4% |
| June 30, 2024 | $18.80M | +109.4% | +21.0% |
| December 31, 2023 | $15.54M | +68.0% | +9.8% |
| September 30, 2023 | $14.16M | +64.9% | +57.7% |
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +48.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2021–2025 period, ELITE PHARMACEUTICALS INC /NV/’s revenue (asc 606) has grown by 231.1% (from $25.38 million to $84.04 million).
- The most recent figure is from ELITE PHARMACEUTICALS INC /NV/’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: